Dr. Reddy’s Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Financial Results:
Dr Reddy’s Laboratories Ltd reported Revenues for Q3FY24 of ₹7,237.00 Crores up from ₹6,790.00 Crore year on year, a rise of 6.58%.
Total Expenses for Q3FY24 of ₹5,627.00 Crores up from ₹5,217.00 Crores year on year, a rise of 7.86%.
Consolidated Net Profit of ₹1,381.00 Crores up 11.01% from ₹1,244.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹82.78, up 10.82% from ₹74.70 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.